Prolongation of Off-Cycle Interval by Finasteride Is Not Associated with Survival Improvement in Intermittent Androgen Deprivation Therapy in LNCaP Tumor Model

    September 2009 in “ The Prostate
    Yujuan Wang, Shubham Gupta, Vi N. Hua, Raquel Ramos-Garcia, Daniel H. Shevrin, Borko Jovanovic, Joel B. Nelson, Zhou Wang
    Image of study
    TLDR Finasteride doesn't improve survival in LNCaP tumor model during off-cycle of therapy.
    This study investigated whether prolonging the off-cycle interval by finasteride is associated with survival improvement in intermittent androgen deprivation therapy (IADT) in LNCaP tumor model. The results showed that prolonging the off-cycle interval by finasteride did not improve survival in IADT in LNCaP tumor model. The study concluded that maximum possible lengthening of the off-cycle by 5α-reductase inhibition is not associated with survival improvement in this animal model.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results

    Related Community Posts Join

    6 / 1000+ results

    Related Research

    3 / 3 results